Celiac.com 06/11/2009 - Specialty pharmaceutical and diagnostic company, Prometheus Laboratories Inc., announced new findings regarding a correlation between an important serologic marker used in the detection of Crohn's disease and particular genetic markers in patients at risk for celiac disease.

Using proprietary Prometheus technology, researchers analyzed blood and serum samples from 5,406 patients at risk for celiac disease who are EMA positive. Results showed a significant correlation between antibodies to the flagellin CBir1 and